HCPCS Code Applications and Approvals: October 2024
Quarterly archive · CMS Level II HCPCS36 coding decisions from the Second Quarter 2024 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Second Quarter 2024 coding cycle, which took effect October 1, 2024.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
October 2024
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9610 | XENOVIEW Xenon xe-129 hyperpolarized gas, diagnostic, per study dose | Polarean Inc. | ReplacesC9150 | Establish | |
| C9150 | XENOVIEW Xenon xe-129 hyperpolarized gas, diagnostic, per study dose | Polarean Inc. | Replaced byA9610 | Discontinue | |
| J0138 | COMBOGESIC IV 505(b)(2) Injection, acetaminophen 10 mg and ibuprofen 3 mg | Hikma Pharmaceuticals USA Inc. Intravenous | — | Establish | |
| J0175 | KISUNLA Injection, donanemab-azbt, 2 mg | Lilly Intravenous | — | Establish | |
| J1170 | Hydromorphone Injection, hydromorphone, up to 4 mg | — | Replaced byJ1171 | Discontinue | |
| J1171 | Hydromorphone Injection, hydromorphone, 0.1 mg | — | ReplacesJ1170 | Establish | |
| J1749 | AURLUMYN 505(b)(2) Injection, iloprost, 0.1 mcg | Eicos Sciences, Inc. Intravenous | — | Establish | |
| J2001 | Lidocaine Hcl For Intravenous Infusion Injection, lidocaine hcl for intravenous infusion, 10 mg | — Intravenous | — | Discontinue | |
| J2002 | Lidocaine Hcl In 5% Dextrose Injection, lidocaine hcl in 5% dextrose, 1 mg | — | — | Establish | |
| J2003 | Lidocaine Hydrochloride Injection, lidocaine hydrochloride, 1 mg | — | — | Establish | |
| J2004 | Lidocaine Hcl With Epinephrine injection, lidocaine hcl with epinephrine, 1 mg | — | — | Establish | |
| J2251 | Midazolam In 0.9% Sodium Chloride Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to J2250, 1 mg | — | — | Revise | |
| J2252 | Midazolam In 0.8% Sodium Chloride 505(b)(2) Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to J2250, 1 mg | — | — | Establish | |
| J2253 | Midazolam (Seizalam) Injection, midazolam (seizalam), 1 mg | — | — | Establish | |
| J2601 | Baxter's Vasopressin in Sodium Chloride Injection 505(b)(2) Injection, vasopressin (baxter), 1 unit | Baxter Healthcare Corporation Intravenous | — | Establish | |
| J8520 | Capecitabine Capecitabine, oral, 150 mg | — | Replaced byJ8522 | Discontinue | |
| J8521 | Capecitabine Capecitabine, oral, 500 mg | — | Replaced byJ8522 | Discontinue | |
| J8522 | Capecitabine Capecitabine, oral, 50 mg | — | ReplacesJ8520ReplacesJ8521 | Establish | |
| J8541 | Dexamethasone (Hemady) Dexamethasone (hemady), oral, 0.25 mg | — | — | Establish | |
| J9172 | DOCIVYX 505(b)(2) Injection, docetaxel (docivyx), 1 mg | Avyxa Holdings, LLC | — | Revise | |
| J9258 | Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) 505(b)(2) Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg | — | — | Discontinue | |
| J9329 | TEVIMBRA Injection, tislelizumab-jsgr, 1 mg | BeiGene USA, Inc. Intravenous | — | Establish | |
| Q4334 | AmnioPlast 1 Amnioplast 1, per square centimeter | — | — | Establish | |
| Q4335 | AmnioPlast 2 Amnioplast 2, per square centimeter | — | — | Establish | |
| Q4336 | Artacent C Artacent c, per square centimeter | Tides Medical | — | Establish | |
| Q4337 | Artacent Trident Artacent trident, per square centimeter | Tides Medical | — | Establish | |
| Q4338 | Artacent Velos Artacent velos, per square centimeter | Tides Medical | — | Establish | |
| Q4339 | Artacent VeriClen Artacent vericlen, per square centimeter | Tides Medical | — | Establish | |
| Q4340 | SimpliGraft Simpligraft, per square centimeter | Xtant Medical | — | Establish | |
| Q4341 | SimpliMax Simplimax, per square centimeter | Xtant Medical | — | Establish | |
| Q4342 | TheraMend Theramend, per square centimeter | Lux Therapeutics | — | Establish | |
| Q4343 | Dermacyte AC Matrix Amniotic Membrane Allograft Dermacyte ac matrix amniotic membrane allograft, per square centimeter | Merakris Therapeutics, Inc. | — | Establish | |
| Q4344 | Tri-Membrane Wrap Tri-membrane wrap, per square centimeter | BioLab Topical | — | Establish | |
| Q4345 | Matrix HD Allograft Dermis Matrix hd allograft dermis, per square centimeter | Royal Wound-X, Inc, RTI Surgical, Inc | — | Establish | |
| Q5135 | TYENNE Biosimilar Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg | Fresenius Kabi Intravenous/Subcutaneous | — | Establish | |
| Q5136 | JUBBONTI/WYOST Biosimilar Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | Sandoz Inc. Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Second Quarter 2024 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
